Selank dosage and protocol
Selank dosage has not been set by any published human study we could find. This page lays out what the research does cover, what is still unknown and where Selank stands legally. Selank is a synthetic seven-amino-acid peptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro), described in the Russian literature as an anti-anxiety drug and as an analog of tuftsin.
What Selank dosage is on record?
No tested human doseNo human dose could be verified: none of the human study abstracts gives an amount.
Checked 11 Nov 2026 against labels, PubMed and the US and Canadian regulators.
What Selank is
Selank is a synthetic seven-amino-acid peptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro), described in the Russian literature as an anti-anxiety drug and as an analog of tuftsin. (1)
Other names and codes used in the research: TP-7, selank acetate, Thr-Lys-Pro-Arg-Pro-Gly-Pro.
How Selank works
Selank is a seven amino acid peptide built on tuftsin, a four amino acid piece of the heavy chain of human immunoglobulin G. The starting material is a fragment of one of the body's own antibodies. (2)
Three extra amino acids were stuck on the tail end, and the reason was survival time rather than activity: the tail makes the molecule harder for enzymes to chew up. (2)
The clearest mechanism finding is at the GABA receptor, the same target benzodiazepines work on. In binding studies the peptide behaved as a positive allosteric modulator, meaning it does not switch the receptor on itself but changes how it answers GABA. (3)
It is not simply a weak benzodiazepine, though. In the same work the peptide blocked what diazepam and olanzapine were doing at the receptor, so the binding sites overlap at most partly. (3)
A second mechanism is enzyme blocking. The peptide slows the enzymes that destroy enkephalins, the body's own opioid signals, though it is half as potent at this as semax. (4)
That effect is not spread evenly across the molecule. Cutting the peptide to five amino acids kept the enzyme-blocking action; three, four and six amino acid pieces lost it. (4)
Among the enkephalin-cutting enzymes it is selective, hitting the ones that trim from the tail end of the chain rather than the head. (5)
Gene activity is the third proposed route. One intraperitoneal dose in rats changed the expression of 45 of 84 genes tied to nerve signalling within an hour, with 22 still changed at three hours. (6)
Those gene changes tracked the changes caused by GABA itself, which is the main argument that the peptide works through the GABA system rather than beside it. (6)
The picture is muddier in human cells. In a human nerve-cell line, the peptide on its own changed none of the 84 gene readouts measured. (7)
What it did do in those human cells was cancel GABA's own effect on gene expression, which the authors read as partial support for the receptor story. (7)
The opioid system appears to be involved as well. Blocking opioid receptors with naloxone cut the anxiety effect in one mouse strain while increasing it in another, so the peptide's action depends on the animal's own opioid tone. (8)
Where Selank came from
The peptide came out of a Moscow institute, not a company: it was designed and produced at the Institute of Molecular Genetics of the Russian Academy of Sciences, working with a pharmacology institute. (2)
Its first name in the literature is TP-7, and the earliest published comparison, from 1995, pitted it against plain tuftsin in rats and found the longer peptide stronger. (9)
By 1998 the selling point was already a wide safe range rather than strength: in anxious mice the peptide worked across a fifteen-fold span of amounts given into the abdomen. (10)
The claim that set it apart from benzodiazepines from the start was the absence of the sedation and dulling those drugs cause, even at the top of that range. (10)
It was developed as one of a set. A 2003 paper compared ten peptides of the tuftsin family side by side for stress behaviour, with this one as the lead candidate. (11)
In the US it is sold mixed with semax. FDA's 2026 review of semax noted products marketed both as single peptides and as combinations. (12)
Selank dosage: what the human data shows
No published human study gave Selank at a stated dose that we could find. That means there is no tested Selank dosage to report, only what animal and lab studies used, which are not human doses. The Selank calculator still works with any amount you enter.
How to reconstitute Selank
Selank comes as a dry powder (5 mg vials). Reconstituting it means adding bacteriostatic water so it can be drawn into a syringe. The water does not change how much Selank is in the vial, only how strong each mL is, so it decides how many syringe units a dose takes.
| Vial | Water | Strength | What 10 units holds | Doses between 5 and 100 units |
|---|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL | 500 mcg in every 10 units | 250 mcg to 5 mg |
| 5 mg | 2 mL | 2.5 mg/mL | 250 mcg in every 10 units | 125 mcg to 2.5 mg |
| 5 mg | 3 mL | 1.667 mg/mL | 167 mcg in every 10 units | 83 mcg to 1.67 mg |
The last column is the range of doses that land between the 5 unit mark (small marks are hard to read) and the 100 unit mark of a 1 mL U-100 syringe for that mix. All of it is arithmetic.
Reconstitution steps
- Wash your hands, work in a clean area and set out the Selank vial, bacteriostatic water, a sterile syringe, alcohol pads and a sharps container (14).
- Check the vial and the water: right product, in date, intact cap (14).
- Wipe both rubber tops with an alcohol pad and let them dry (14).
- Draw the water amount you picked from the table into the syringe.
- Push the needle through the Selank vial stopper and let the water in slowly.
- Move the vial in a circle until the powder is fully dissolved. Do not shake it (15).
- Check the liquid. MedlinePlus says not to use it if it has changed color, has floating pieces or is cloudy (14).
- Write the date you mixed it on the vial (14), and note the water amount so every later draw uses the same numbers.
After mixing
No published storage data exists for mixed Selank; the bacteriostatic water label says not to store a mixed drug unless its maker says you can (13).
For any other vial size, water amount or dose, use the Selank reconstitution calculator.
Selank dosage and half-life
No human pharmacokinetic figure exists. What has been measured, in rats using a tritium-labelled peptide, is the breakdown path: the peptide is cut back to a five amino acid piece, then a three amino acid piece, then pairs. (16)
The only pharmacokinetic study found was in rat brain tissue after the peptide was given into the nose, so even the animal data are route-specific. (16)
Four routes were compared head to head in rats. For getting the peptide to the brain, the nose won. (17)
That same study turned up something unexpected: whichever way it was given, the peptide piled up in stomach tissue, which is where the gastric effects reported for this family come from. (17)
Stability is the designed-in feature of the molecule, and the authors argue it is high enough that the peptide survives the gut, which would allow it to be swallowed rather than injected. (18)
What the Selank research found
In people
- Randomized trialGeneralized anxiety disorder and neurasthenia (62 patients): Selank in 30 patients was compared with the benzodiazepine medazepam in 32. Anxiety relief was similar, and Selank also reduced fatigue. PubMed indexes this as a randomized controlled trial; the abstract does not describe randomization or blinding. (19)Source text: “The anxiolytic effects of both drugs were similar but selank had also antiasthenic and psychostimulant effects.”
- Small human studyPhobic-anxiety and somatoform disorders (60 patients), Selank compared with phenazepam: the authors reported a pronounced anti-anxiety effect that lasted a week after the last dose. (20)Source text: “The anxiolytic effect lasted for a week after last receiving the peptide.”
- Randomized trialAnxiety disorders (70 patients): phenazepam alone in 30 was compared with Selank plus phenazepam in 40. The combination worked sooner on a rating scale and reduced phenazepam's side effects. PubMed indexes this as a randomized controlled trial; the abstract does not describe randomization or blinding. (21)Source text: “The combined treatment decreased the level of undesirable side-effects of phenazepam”
- Small human studyPatients with generalized anxiety disorder and neurasthenia who received Selank for 14 days showed a shift in blood cytokine balance. (22)Source text: “in the serum of patients with generalized anxiety disorder and neurasthenia who received Selank during 14 days”
- Small human studyHealthy participants (52 in all): brain scans before and 5 and 20 minutes after Semax, Selank or placebo showed a difference in connectivity between the right amygdala and the temporal cortex. (23)Source text: “Resting-state fMRI was carried out three times, namely before, after 5 and 20 min of the injection of either Semax, or Selank, or placebo.”
- Small human studyUS regulators have not assessed this peptide. When FDA reviewed semax in 2026, a selank paper submitted with the nomination was set aside as out of scope, so there is no FDA evaluation of selank to read. (12)Source text: “which is out of the scope of this evaluation and is, therefore, not further discussed”
In animals and in the lab
These results come from animals or cells. They show what researchers are looking at, not what Selank does in people.
- Lab studyIn laboratory tests on plasma, Selank slowed the breakdown of enkephalin, which the authors proposed as a mechanism for its anti-anxiety effect. (1)Source text: “dose-dependently inhibited enzymatic hydrolysis of plasma enkephalin (IC50 15 microM)”
- Animal studyIn rats, a single dose into the nose changed the level of 36 gene transcripts in the hippocampus more than 2-fold. (24)Source text: “mRNA levels of 36 genes changed more than 2-fold after a single intranasal Selank administration”
- Animal studyIn rats under weeks of unpredictable mild stress, the peptide on its own did more for anxiety than diazepam did or than the two together did. (25)Source text: “the individual administration of Selank was the most effective in reducing elevated levels of anxiety”
- Animal studyThe same study contains an awkward result: giving a course of either test substance to unstressed animals made their anxiety measures worse, not better, though less so with the peptide. (25)Source text: “even in the absence of chronic stress, the administration of a course of test substances changed anxiety indicators toward their deterioration”
- Animal studyIn rats made dependent on morphine and then put into withdrawal, a single injection into the abdomen (in rats given 0.3 mg/kg) cut the overall withdrawal score by nearly 40 percent. (26)Source text: “Single intraperitoneal injection of Selank in an anxiolytic dose of 0.3 mg/kg reduced the total index of morphine withdrawal syndrome by 39.6%”
- Animal studyDiazepam still beat it in that experiment, cutting the same score by about half, so the peptide was second best on withdrawal signs. (26)Source text: “Selank was slightly inferior to diazepam in a dose of 2 mg/kg by pharmacological activity”
- Animal studyIn rats that had drunk alcohol for 30 weeks, a week of the peptide (in rats given 0.3 mg/kg a day) prevented the memory and attention problems that show up during withdrawal. (27)Source text: “Selank (0.3 mg/kg a day, 7 days, intraperitoneally) produced a cognitive-stimulating effect in 9 months rats not exposed to ethanol”
- Animal studyThe brain-chemistry side of that study is the opposite of the usual peptide marketing line: the peptide stopped a rise in BDNF rather than raising it. (27)Source text: “Selank prevented ethanol-induced increase in BDNF content in the hippocampus and frontal cortex (p<0.05)”
- Animal studyIn rats with a chemical model of Parkinson's disease, the peptide brought anxiety down but did nothing for movement, which is the symptom that matters in that disease. (28)Source text: “both peptides did not affect motor activity of rats in elevated cross shaped maze and passive defensive behavior of the animals”
- Animal studyThe anxiety effect in that model held up despite the damage to dopamine nerve cells, which the authors took as a sign the peptide does not need that system to work. (28)Source text: “Selank decreased level of anxiety of rats with toxic damage of DA neurons in elevated cross shaped maze”
- Animal studyIn monkeys made neurotic, the peptide given into the nose produced lasting changes in behaviour, with fear and aggression dropping away and more exploring and handling. (29)Source text: “an intranasal administration of Selank produces long-term changes of the monkeys' behavior disturbed during neurosis: elimination of fear and aggression”
- Animal studyA Polish university group, working outside the originating institute, gave it to anxious rats daily for four weeks and saw the effect from day two onward hold for the whole month. (30)Source text: “The heptapeptide reduced the anxiety-phobic states significantly starting from the second day of drug application.”
- Animal studyThat independent study also checked the obvious side effect of a mood drug and found none: body weight was unchanged by the peptide itself. (30)Source text: “TP-7 did not cause any changes in the body mass by itself.”
- Animal studyRoute and genetics decide whether anything happens at all. In mice, the effects appeared only in the strain that was anxious to begin with, whichever way the peptide was given. (31)Source text: “The anxiolytic and nootropic efficiency of selank administered via both routes was observed only in BALB/c mice”
- Animal studyThe route also changed the target. Given into the abdomen it raised GABA receptor binding sites in the frontal cortex by 38 percent, with no change at the glutamate receptor. (31)Source text: “i.p. selank increased the number of [G-(3)H]SR 95531 binding sites with GABA-receptors in the frontal cortex by 38%”
- Animal studyGiven into the nose, the same amount did the reverse: glutamate receptor binding rose by 23 percent and the GABA receptors were untouched. Nose and injection are not interchangeable in this peptide. (31)Source text: “i.n. selank led to an increase in the density of [G-(3)H]MK-801 binding sites by 23% with no effect on GABA receptors”
- Lab studyThe immune side has been tested too. Added to cell cultures a day before flu virus was introduced, the peptide shut down virus production completely. (32)Source text: “Selank added to the cell culture 24 hours before inoculation (a preventive use scheme) showed the highest efficiency, by completely suppressing viral reproduction.”
- Animal studyIn animals, the same study found it switched on interferon-alpha, the body's own antiviral signal, while leaving three inflammatory signals alone. (32)Source text: “The use of Selank in vivo induced the gene expression of interferon-alpha (IFN-alpha), without affecting that of interleukin (IL)-4, IL-10, or tumor necrosis factor-alpha (TNF-alpha).”
- Animal studyOne injection into a mouse changed 34 inflammation-related genes in the spleen within 6 to 24 hours, so the immune effect is not limited to the brain. (33)Source text: “We found significant changes in the expression of 34 genes involved in inflammation processes.”
- Animal studyThe gene that moved most in that experiment was Bcl6, a master switch in immune system development, and it moved with the peptide's fragments as well as the whole peptide. (33)Source text: “the Bcl6 gene, which plays a main role in the formation and development of the immune system, exhibited significant changes in its expression levels”
- Animal studyIn rats kept in social conflict for 20 days (in rats given 100 mcg/kg a day), the peptide brought raised inflammatory signals back toward normal. (34)Source text: “a group that received intraperitoneally Selank at a dose of 100 mcg/kg/day under conditions of 20-day stress”
- Lab studyA toxicity screen in mouse embryonic stem cells found something worth knowing: at high concentration the peptide cut the share of cells becoming GABA nerve cells by 61 percent. (35)Source text: “decrease the ratio of these cells by 61, 58, and 87%, respectively, in comparison with the control”
- Lab studyThe authors of that screen still concluded the peptides were not toxic to developing cells, which is a judgement call readers can weigh against the 61 percent figure. (35)Source text: “Our results indicate that these peptide compounds do not produce toxic effect during the embryonic and fetal period of life.”
- Lab studyIn the same work the peptide had little effect on stem cells turning into mature nerve cells, which argues against the nerve-regeneration claims made for it online. (35)Source text: “HLDF-6, Selank, and thyroliberin produced an insignificant effect on the differentiation of these cells into mature neurons.”
Selank dosage and side effects
What labels and human studies report. A short or small study can miss rare side effects, so an empty list is not proof of safety.
- The abstracts give no side-effect figures for Selank itself. In one study, adding Selank to phenazepam reduced the tranquilizer's side effects, such as impaired attention and memory, weakness and sedation. (21)
- An early paper describes Selank as not causing the side effects typical of most anti-anxiety drugs. The abstract gives no data for that statement. (1)
- A 2021 review from US pharmacy faculty calls Selank poorly studied and notes that it is sold to US consumers as a dietary supplement. (36)
- FDA says it lacks important safety information on selank acetate in humans and names immune reactions from aggregation and peptide impurities as possible risks of compounded product. (37)
Animal safety findings
These come from animal studies, not people, but they are the only safety data on record for some outcomes.
- A toxicity screen in mouse embryonic stem cells found something worth knowing: at high concentration the peptide cut the share of cells becoming GABA nerve cells by 61 percent. (35)
- The authors of that screen still concluded the peptides were not toxic to developing cells, which is a judgement call readers can weigh against the 61 percent figure. (35)
Injecting under the skin
General steps for an injection under the skin, from MedlinePlus (38). Labels for approved products give their own instructions, which come first.
- Pick a site: the belly (below the ribs, above the hip bones and at least 2 inches from the belly button), the outer upper thigh, or the back or side of the upper arm.
- Move to a new spot each time, at least 1 inch from the last one. MedlinePlus says this keeps the skin healthy and helps the body absorb the medicine.
- Wash your hands with soap and running water for at least 1 minute, dry them, then clean the skin with an alcohol pad and let it dry.
- Pinch about an inch of skin and fat, put the needle in quickly at 90 degrees (45 degrees if there is little fat), let go of the skin and push the plunger all the way.
- Pull the needle out, put it straight into a sharps container, and press clean gauze on the spot for a few seconds. Never reuse a needle or syringe.
- Some soreness is expected. MedlinePlus says to contact a health care provider for signs of infection such as redness, swelling, red streaks or fever.
To draw the right amount, use the Selank calculator and the drawing steps on that page.
Is Selank banned in sport?
Sport status has changed since this compound's fact file was written. On the prohibited list in force from 1 January 2027, peptides are named as a class in S0, the group banned at all times. (39)
S0 is the catch-all for drugs with no human approval from any health authority anywhere, which covers this peptide outside Russia. (39)
Selank is not listed by name among the example peptides, and the US anti-doping agency warns that this means nothing in practice. (39)
The agency's reason for naming peptides as a class is that unapproved peptides already satisfy the code's own test for banning a substance. (39)
Is Selank legal in the US and Canada?
FDA page content current as of 2026-04-22. openFDA searches of Drugs@FDA and of drug labels for selank returned no match on 2026-10-10.
Advisory dated 2025-08-01. Drug Product Database searches for selank by ingredient and by brand returned no rows on 2026-10-10 (S12).
What is still unknown
- No human dose could be verified: none of the human study abstracts gives an amount.
- The route is unverified too. The clinical abstracts do not state it, and one imaging abstract uses the word injection with no detail. It should not be assumed that patients were given Selank into the nose.
- The human studies found are small comparisons with benzodiazepines (60 to 70 patients each) published in one Russian-language journal. PubMed indexes two of them as randomized controlled trials, but their abstracts do not describe randomization or blinding. None is registered on ClinicalTrials.gov.
- Not approved in the US or Canada as of the check date. A 2021 review describes Selank as a poorly studied Russian drug sold to US consumers as a dietary supplement (S8).
- A Belgian public health laboratory that identified Selank and Semax in seized products wrote that, to its knowledge, they had not completed any clinical trials, and that they are sold online as powder for injection or in nasal sprays (S9).
- Health Canada named Selank among unauthorized injectable peptide drugs seized from an online seller (S11).
- FDA compounding status: on the FDA page current as of 2026-04-22, Selank is not in the table of substances now in category 2. It is in a separate list of substances that were in category 2 and were then withdrawn by their nominators (S10).
- No dose amount in any PubMed abstract of a human Selank study, so the doses list is empty. The abstracts give patient numbers and in one case a 14-day course, but no figure in mg or mcg.
- Route in the human studies: not stated in the abstracts. One brain-imaging abstract uses the word injection without more detail (S6); the rat study gave it into the nose (S7).
- No human half-life or pharmacokinetic figure. A PubMed search for selank with pharmacokinetics, half-life or bioavailability returned only mouse and laboratory studies.
- No label was retrieved. The Russian state register of medicines needs a captcha to search, so the Russian registration and label dose are not recorded here and the products list is empty.
- No Selank trial registered on ClinicalTrials.gov: a search for selank as the intervention returned only two unrelated brain-stimulation studies.
- Not named on the WADA Prohibited List (page checked 2026-10-10, S13). The list also has an open class, S0, for substances with no current approval by any governmental health authority for human therapeutic use; whether it applies to this compound was not determined here.
- No new human study of this peptide was found. Everything added here is rats, mice, monkeys or cells, and the human record is still the small Russian comparisons already in the fact file.
- No fetched source in this session shows selank registered as a medicine in Russia or anywhere else. Papers call it a drug, but registration could not be confirmed from a regulator's own record.
- No human pharmacokinetic figure exists: no half-life, no blood level, no bioavailability. The breakdown path and brain delivery data are from rats (X7, X8).
- No amount given to a person has been published in any abstract read, so the amounts in circulation have no trial behind them.
- US regulators have never evaluated selank. FDA's July 2026 compounding review covered semax and epitalon but explicitly set a selank paper aside as out of scope (X23).
- The GABA receptor mechanism is supported in rat tissue but not in human cells, where the peptide alone changed nothing measurable (X3).
- Route matters and is unsettled: in mice, into the abdomen and into the nose hit different receptor systems (X10), so results from one route should not be read across to the other.
- Nobody has published a toxicity programme: no acute or repeat-dose study, no genotoxicity work, and only one stem cell screen that touches developmental safety (X16).
- The WADA prohibited list PDF could not be opened in this session (the site returned an empty response), so sport status is quoted from the US anti-doping agency's advisory about that list.
Selank dosage questions
Is there a proven Selank dosage?
No. No published human study gave a stated dose of Selank that we could find.
Is Selank approved?
Not FDA approved. FDA lists selank acetate (TP-7) among bulk substances that were in compounding category 2 and whose nominations were then withdrawn. No Selank product in the Health Canada Drug Product Database. Health Canada named Selank among unauthorized injectable peptide drugs seized from an online seller.
What side effects of Selank have been reported?
The abstracts give no side-effect figures for Selank itself. In one study, adding Selank to phenazepam reduced the tranquilizer's side effects, such as impaired attention and memory, weakness and sedation. An early paper describes Selank as not causing the side effects typical of most anti-anxiety drugs. The abstract gives no data for that statement.
Is Selank banned in sport?
Sport status has changed since this compound's fact file was written. On the prohibited list in force from 1 January 2027, peptides are named as a class in S0, the group banned at all times.
How many units of Selank do I draw?
Use the Selank calculator: pick your vial, water and dose, and it gives the units on a U-100 insulin syringe.
Sources
- Zozulya AA et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bull Exp Biol Med 2001. PubMed 11550013
- Volkova A et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission (full text). Front Pharmacol 2016. PubMed 26924987
- Vyunova TV et al. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein Pept Lett 2018. PubMed 30255741
- Kost NV et al. [Semax and selank inhibit the enkephalin-degrading enzymes from human serum]]. Bioorg Khim 2001. PubMed 11443939
- Zolotarev IuA et al. [Leu-enkephalin homogeneously labeled with tritium in studying the Selank inhibiting effect on the enkephalin-degrading enzymes of human plasma]. Bioorg Khim 2004. PubMed 15344652
- Volkova A et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol 2016. PubMed 26924987
- Filatova E et al. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Front Pharmacol 2017. PubMed 28293190
- Kozlovskii II et al. [The role of opioid system in peculiarities of anti-anxiety effect of peptide anxiolytic selank]. Eksp Klin Farmakol 2012. PubMed 22550852
- Seredenin SB et al. [The characteristics of the anxiolytic action of taftsin and its analog TP-7 on behavior and serotonin metabolism in the brain of rats with chronic deprivation of serotoninergic system activity]. Eksp Klin Farmakol 1995. PubMed 8704608
- Seredenin SB et al. [The anxiolytic action of an analog of the endogenous peptide tuftsin on inbred mice with different phenotypes of the emotional stress reaction]. Zh Vyssh Nerv Deiat Im I P Pavlova 1998. PubMed 9583175
- Kozlovskaya MM et al. Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Neurosci Behav Physiol 2003. PubMed 14969422
- FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23-24 2026: Semax-Related Bulk Drug Substances (Semax (free base) and Semax acetate). 2026. fda.gov
- Bacteriostatic Water for Injection, USP (Hospira) label. DailyMed
- MedlinePlus, Drawing medicine out of a vial (reviewed 14 Jan 2026). medlineplus.gov
- Egrifta WR (tesamorelin) US prescribing information, section 2.2. DailyMed
- Zolotarev IuA et al. [Evenly tritium-labeled peptides and their in vivo and in vitro biodegradation]. Bioorg Khim 2006. PubMed 16637290
- Ashmarin IP et al. [A comparative analysis of distribution of glyprolines administered by various routes]. Bioorg Khim 2008. PubMed 18695718
- Ashmarin IP et al. Natural and hybrid ("chimeric") stable regulatory glyproline peptides. Pathophysiology 2005. PubMed 15837162
- Zozulia AA et al. [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]. Zh Nevrol Psikhiatr Im S S Korsakova 2008. PubMed 18454096
- Medvedev VE et al. [A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders]. Zh Nevrol Psikhiatr Im S S Korsakova 2014. PubMed 25176261
- Medvedev VE et al. [Optimization of the treatment of anxiety disorders with selank]. Zh Nevrol Psikhiatr Im S S Korsakova 2015. PubMed 26356395
- Uchakina ON et al. [Immunomodulatory effects of selank in patients with anxiety-asthenic disorders]. Zh Nevrol Psikhiatr Im S S Korsakova 2008. PubMed 18577961
- Panikratova YR et al. Functional Connectomic Approach to Studying Selank and Semax Effects. Dokl Biol Sci 2020. PubMed 32342318
- Kolomin TA et al. [Transcriptome alteration in hippocampus under the treatment of tuftsin analog Selank]. Zh Vyssh Nerv Deiat Im I P Pavlova 2013. PubMed 24450168
- Kasian A et al. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behav Neurol 2017. PubMed 28280289
- Konstantinopolsky MA et al. Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats. Bull Exp Biol Med 2022. PubMed 36322304
- Kolik LG et al. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats. Bull Exp Biol Med 2019. PubMed 31625062
- Slominsky PA et al. Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism. Dokl Biol Sci 2017. PubMed 28702721
- No author list in the PubMed record [Compensatory and antiamnestic effects of heptapeptide Selank in monkeys]. Zh Evol Biokhim Fiziol 2008. PubMed 18727417
- Czabak-Garbacz R et al. Influence of long-term treatment with tuftsin analogue TP-7 on the anxiety-phobic states and body weight. Pharmacol Rep 2006. PubMed 16963804
- Vasil'eva EV et al. [COMPARISON OF PHARMACOLOGICAL EFFECTS OF HEPTAPEPTIDE SELANK AFTER INTRANASAL AND INTRAPERITONEAL ADMINISTRATION TO BALB/c AND C57BL/6 MICE.]. Eksp Klin Farmakol 2016. PubMed 29787664
- Ershov FI et al. [Antiviral activity of immunomodulator Selank in experimental influenza infection]. Vopr Virusol 2009. PubMed 19882898
- Kolomin T et al. Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank. Regul Pept 2011. PubMed 21609736
- Leonidovna YA et al. The Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress. Curr Rev Clin Exp Pharmacol 2021. PubMed 32621722
- Kobylyanskii AG et al. Studying the Toxic Effects of Some Biologically Active Peptides on the Model of Mouse Embryonic Stem Cells. Bull Exp Biol Med 2017. PubMed 29063333
- Doyno CR et al. Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank. J Clin Pharmacol 2021. PubMed 34396551
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. 2026. fda.gov
- MedlinePlus, Subcutaneous (SQ) injections. medlineplus.gov
- Athlete Advisory: What's New on the 2027 WADA Prohibited List?. 2026. usada.org
- Unauthorized injectable peptide drugs seized and sold by Canada Peptide may pose serious health risks. 2025. recalls-rappels.canada.ca
Facts checked 10 Oct 2026 and 11 Nov 2026 against the sources above. This page reports what labels and published studies used. It is not medical advice: talk to a licensed prescriber before you start, stop or change anything.